Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-adrenoceptor blockade: past, present, and future.

C T Dollery1

  • 1Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, U.K.

Journal of Cardiovascular Pharmacology
|January 1, 1988
PubMed
Summary

Beta-blockers, initially for angina, effectively reduce mortality post-myocardial infarction. While their impact on hypertension is modest, ongoing research explores new beta-blocker developments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Concise Guide to PHARMACOLOGY 2013/14: overview.

British journal of pharmacology·2014
Same author

Intracellular drug concentrations.

Clinical pharmacology and therapeutics·2013
Same author

Acute effects of varying doses of propranolol upon oxygen haemoglobin affinity in man.

British journal of clinical pharmacology·2012
Same author

Metabolism of terbutaline in man and dog.

British journal of clinical pharmacology·2012
Same author

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.

Clinical pharmacology and therapeutics·2012
Same author

Chairman's Introduction.

Proceedings of the Royal Society of Medicine·2010

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-adrenoceptor blocking drugs were initially developed for angina pectoris.
  • Their antihypertensive properties were discovered serendipitously during angina trials.

Purpose of the Study:

  • To review the efficacy and development of beta-blockers in cardiovascular medicine.
  • To assess the impact of ancillary properties on beta-blocker outcomes.
  • To explore future directions in beta-blocker research.

Main Methods:

  • Review of clinical trials and observational data on beta-blocker use.
  • Analysis of secondary prevention trials post-myocardial infarction.
  • Examination of primary prevention data from hypertensive patient trials.

Main Results:

Related Experiment Videos

  • Beta-blockers significantly reduce mortality (25-30%) in the first 2-3 years after acute myocardial infarction.
  • Ancillary properties have minimal impact on angina and hypertension efficacy but affect adverse reactions.
  • Hypertension trials show a modest 6% reduction in acute myocardial infarction incidence.

Conclusions:

  • Beta-blockade remains a cornerstone in managing cardiovascular diseases, particularly post-myocardial infarction.
  • Further development of beta-blockers, including novel combinations and ancillary properties, holds promise.
  • Research continues to refine the application and development of beta-adrenoceptor blocking drugs.